Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
59
SYRE Quote, Financials, Valuation and Earnings
Last price:
$33.11
Seasonality move
:
14.35%
Day range:
$32.79 - $34.10
52-week range:
$10.91 - $35.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
701.12x
P/B ratio:
5.63x
Volume:
292K
Avg. volume:
814.3K
1-year change:
41.6%
Market cap:
$2.6B
Revenue:
--
EPS (TTM):
-$2.18
Analysts' Opinion
-
Consensus RatingSpyre Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $54.29, Spyre Therapeutics, Inc. has an estimated upside of 64.25% from its current price of $33.05.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $21.00 representing 36.46% downside risk from its current price of $33.05.
Fair Value
-
According to the consensus of 16 analysts, Spyre Therapeutics, Inc. has 64.25% upside to fair value with a price target of $54.29 per share.
SYRE vs. S&P 500
-
Over the past 5 trading days, Spyre Therapeutics, Inc. has underperformed the S&P 500 by -1.44% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Spyre Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Spyre Therapeutics, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Spyre Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Spyre Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Spyre Therapeutics, Inc. reported earnings per share of -$0.18.
Enterprise value:
2.1B
EV / Invested capital:
4.57x
Price / LTM sales:
701.12x
EV / EBIT:
--
EV / Revenue:
443.75x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-12.81x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-24.15%
Net Income Margin (TTM):
--
Return On Equity:
-28.51%
Return On Invested Capital:
-28.51%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.1M | -- | -- | -- | -- | |
| Gross Profit | -$400K | -- | -- | -- | -- | |
| Operating Income | -$100M | -$195.1M | -$223.6M | -$55.4M | -$56.9M | |
| EBITDA | -$98.5M | -$195.1M | -$223.6M | -$55.4M | -$56.9M | |
| Diluted EPS | -$78.22 | $9.21 | -$2.18 | -$1.06 | -$0.18 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $117.5M | $82.2M | $205.9M | $421.1M | $504.6M | |
| Total Assets | $129.1M | $91.6M | $207.3M | $421.1M | $504.6M | |
| Current Liabilities | $20.4M | $17.7M | $44.9M | $57.5M | $46.3M | |
| Total Liabilities | $27M | $24M | $452.7M | $93.7M | $49.5M | |
| Total Equity | $102.1M | $67.6M | -$245.4M | $327.4M | $455.1M | |
| Total Debt | $4.7M | $4.2M | $387.1M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$87M | -$151.3M | -$162.3M | -$29.5M | -$37.1M | |
| Cash From Investing | -$59.1M | -$218M | -$66.6M | $42.7M | $25M | |
| Cash From Financing | $197.5M | $349M | $222.2M | $12.9M | -$4.6M | |
| Free Cash Flow | -$87M | -$151.3M | -$162.3M | -$29.5M | -$37.1M | |
SYRE
Sector
Market Cap
$2.6B
$28M
Price % of 52-Week High
93.6%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-22.45%
-1.54%
1-Year Price Total Return
41.6%
-17.48%
Beta (5-Year)
3.136
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$33.34
200-day SMA
Buy
Level
$18.78
Bollinger Bands (100)
Buy
Level
15.56 - 28.28
Chaikin Money Flow
Sell
Level
-3.2M
20-day SMA
Buy
Level
$32.68
Relative Strength Index (RSI14)
Buy
Level
61.97
ADX Line
Buy
Level
20.13
Williams %R
Neutral
Level
-74.0984
50-day SMA
Buy
Level
$27.27
MACD (12, 26)
Buy
Level
8.78
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Sell
Level
-2.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.0376)
Sell
CA Score
(Annual)
Level (-1.3497)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.2047)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Stock Forecast FAQ
In the current month, SYRE has received 16 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SYRE average analyst price target in the past 3 months is $54.29.
-
Where Will Spyre Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Spyre Therapeutics, Inc. share price will rise to $54.29 per share over the next 12 months.
-
What Do Analysts Say About Spyre Therapeutics, Inc.?
Analysts are divided on their view about Spyre Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Spyre Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $21.00.
-
What Is Spyre Therapeutics, Inc.'s Price Target?
The price target for Spyre Therapeutics, Inc. over the next 1-year time period is forecast to be $54.29 according to 16 Wall Street analysts, 16 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SYRE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Spyre Therapeutics, Inc. is a Buy. 16 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SYRE?
You can purchase shares of Spyre Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Spyre Therapeutics, Inc. shares.
-
What Is The Spyre Therapeutics, Inc. Share Price Today?
Spyre Therapeutics, Inc. was last trading at $33.11 per share. This represents the most recent stock quote for Spyre Therapeutics, Inc.. Yesterday, Spyre Therapeutics, Inc. closed at $33.05 per share.
-
How To Buy Spyre Therapeutics, Inc. Stock Online?
In order to purchase Spyre Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SYRE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SYRE
Sector
P/E ratio
--
23.89x
PEG ratio
0.00x
-0.01x
P/B ratio
5.63x
1.82x
Price / LTM sales
701.12x
1.60x
Growth Metrics
SYRE
Sector
Revenue growth
--
4.62%
Earnings growth
82.57%
10.88%
Revenue (5-year growth)
-25.61%
6.5%
Earnings forecast
-$0.74
-$0.21
Profitability
SYRE
Sector
Profitability FY 2024
--
$3.5M
Return on invested capital
-28.51%
-31.77%
Return on assets
-24.15%
-27.96%
Return on equity
-28.51%
-37.63%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
3
Balance Sheet
SYRE
Sector
Total cash
$486.2M
$26.3M
Short term investments
$513.7M
$25.7M
Total assets
$608.5M
$78M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
